Market Summary
USD78.83+5.59
Market Closed7.63%
LNTH Stock Price
LNTH RSI Chart
LNTH Valuation
LNTH Price/Sales (Trailing)
LNTH Profitability
LNTH Fundamentals
LNTH Revenue
LNTH Earnings
Price Action
52 Week Range
47.4687.47
(Low)(High)
Last 7 days
-2.7%
Last 30 days
26.0%
Last 90 days
38.9%
Trailing 12 Months
39.3%
LNTH Financial Health
LNTH Investor Care
Peers (Alternatives to Lantheus Holdings)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
DHR | 181.6B | 31.5B | -6.84% | -10.46% | 25.19 | 5.77 | 6.85% | 12.06% |
ABT | 173.6B | 43.7B | -9.88% | -15.65% | 25.04 | 3.98 | 1.34% | -1.95% |
MDT | 105.5B | 30.8B | -7.09% | -24.59% | 25.94 | 3.43 | -3.19% | -17.38% |
IDXX | 39.3B | 3.4B | -6.38% | -7.55% | 57.87 | 11.67 | 4.73% | -8.83% |
WST | 24.9B | 2.9B | 19.13% | -15.53% | 42.55 | 8.63 | 1.95% | -11.47% |
| MID-CAP | ||||||||
PEN | 10.2B | 847.1M | -3.64% | 34.52% | -5.1K | 12.05 | 13.32% | -137.89% |
LNTH | 5.4B | 935.1M | 25.97% | 39.32% | 193.26 | 5.8 | 119.91% | 139.38% |
NEOG | 4.0B | 630.7M | -10.17% | -47.35% | -245.45 | 6.32 | 25.40% | -128.45% |
QDEL | 3.7B | - | -1.66% | -18.22% | 3.27 | 1.42 | - | - |
| SMALL-CAP | ||||||||
VIVO | 1.5B | 301.6M | 2.29% | 56.91% | -550.1 | 4.93 | -3.75% | -104.51% |
CYRX | 1.1B | 237.3M | -1.49% | -23.16% | -24.39 | 4.66 | 6.59% | 84.02% |
HSKA | 930.1M | 257.3M | 4.78% | -40.89% | -46.77 | 3.61 | 1.41% | -1632.49% |
AWH | 54.7M | 7.9M | -24.44% | -58.25% | -1.76 | 6.95 | 23.02% | -7.81% |
QTNT | 766.7K | 37.4M | -50.00% | -99.61% | -0.01 | 0.02 | -2.49% | 10.49% |
Financials for Lantheus Holdings
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 16.7% | 935 | 801 | 664 | 542 | 425 |
| Gross Profit | 23.1% | 582 | 472 | 368 | 276 | 188 |
| S&GA Expenses | 8.2% | 100 | 93.00 | 84.00 | 75.00 | 68.00 |
| R&D Expenses | 514.2% | 312 | 51.00 | 49.00 | 47.00 | 45.00 |
| EBITDA | -62.2% | 82.00 | 216 | 114 | 21.00 | - |
| EBITDA Margin | -67.6% | 0.09* | 0.27* | 0.17* | 0.04* | - |
| Earnings Before Taxes | -83.5% | 27.00 | 162 | 59.00 | -31.48 | -75.04 |
| EBT Margin | -85.9% | 0.03* | 0.20* | 0.09* | -0.06* | - |
| Interest Expenses | 17.2% | 7.00 | 6.00 | 6.00 | 7.00 | 8.00 |
| Net Income | -73.8% | 28.00 | 107 | 32.00 | -37.33 | -71.28 |
| Net Income Margin | -77.5% | 0.03* | 0.13* | 0.05* | -0.07* | - |
| Free Cahsflow | 48.1% | 282 | 190 | 101 | 54.00 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | 20.6% | 1,321 | 1,096 | 1,014 | 933 | 864 |
| Current Assets | 35.0% | 678 | 502 | 404 | 325 | 236 |
| Cash Equivalents | 61.6% | 416 | 257 | 171 | 105 | 99.00 |
| Inventory | 2.0% | 35.00 | 35.00 | 34.00 | 34.00 | 35.00 |
| Goodwill | 0% | 61.00 | 61.00 | 61.00 | 61.00 | 61.00 |
| Liabilities | 90.9% | 874 | 458 | 446 | 417 | 399 |
| Current Liabilities | 5.0% | 248 | 236 | 219 | 178 | 90.00 |
| Long Term Debt | -2.3% | 152 | 156 | 159 | 163 | - |
| LT Debt, Current | -97.7% | 0.00 | 15.00 | 14.00 | 13.00 | 12.00 |
| LT Debt, Non Current | 241.9% | 558 | 163 | - | - | - |
| Shareholder's Equity | -29.9% | 447 | 638 | 567 | 516 | 464 |
| Retained Earnings | -161.1% | -193 | -73.97 | -135 | -178 | -221 |
| Additional Paid-In Capital | 1.1% | 716 | 708 | 700 | 692 | 685 |
| Accumulated Depreciation | - | 89.00 | - | - | - | - |
| Shares Outstanding | 0.1% | 69.00 | 69.00 | 69.00 | 68.00 | - |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | 48.1% | 282 | 190 | 101 | 54.00 | 54.00 |
| Share Based Compensation | 15.7% | 29.00 | 25.00 | 21.00 | 18.00 | 16.00 |
| Cashflow From Investing | -1589.7% | -276 | -16.37 | -12.70 | -11.01 | 4.00 |
| Cashflow From Financing | 3878.5% | 312 | -8.25 | -8.02 | -6.72 | -39.33 |
| Buy Backs | Infinity% | 75.00 | 0.00 | - | - | - |
Risks for LNTH
What is the probability of a big loss on LNTH?
89.6%
Probability that Lantheus Holdings stock will be more than 20% underwater in next one year
61.1%
Probability that Lantheus Holdings stock will be more than 30% underwater in next one year.
37.7%
Probability that Lantheus Holdings stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does LNTH drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Lantheus Holdings was unfortunately bought at previous high price.
Drawdowns
Returns for LNTH
Cumulative Returns on LNTH
67.3%
7-Year Cumulative Returns
35.2%
5-Year Cumulative Returns
78.3%
3-Year Cumulative Returns
What are the long-term rolling returns for LNTH?
FIve years rolling returns for Lantheus Holdings.
Annualized Returns
Which funds bought or sold LNTH recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | sold off | -100 | -268,000 | - | -% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -15.27 | -1,933,280 | 3,074,720 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | unchanged | - | -32,000 | 83,000 | -% |
2023-02-28 | Voya Investment Management LLC | added | 63.61 | 2,420,830 | 15,472,800 | 0.02% |
2023-02-27 | Parallax Volatility Advisers, L.P. | new | - | 6,829 | 6,829 | -% |
2023-02-24 | NATIXIS | reduced | -3.47 | -429,517 | 909,483 | -% |
2023-02-22 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | reduced | -31.71 | -650,000 | 636,000 | 0.01% |
2023-02-21 | MACQUARIE GROUP LTD | reduced | -99.87 | -27,391,000 | 25,000 | -% |
2023-02-21 | Empowered Funds, LLC | added | 137 | 1,248,960 | 2,983,960 | 0.20% |
2023-02-21 | NORTHWESTERN MUTUAL INVESTMENT MANAGEMENT COMPANY, LLC | new | - | 324,615 | 324,615 | 0.01% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Lantheus Holdings News
Schedule 13G FIlings of Lantheus Holdings
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 10.53% | 7,247,124 | SC 13G/A | |
| Jan 26, 2023 | blackrock inc. | 11.9% | 8,203,470 | SC 13G/A | |
| Jan 20, 2023 | blackrock inc. | 11.9% | 8,203,470 | SC 13G/A | |
| Jul 11, 2022 | vanguard group inc | 10.84% | 7,438,724 | SC 13G/A | |
| Feb 15, 2022 | armistice capital, llc | 0% | 0 | SC 13G/A | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 3.1% | 2,165,371 | SC 13G/A | |
| Feb 04, 2022 | wellington trust co n a | 1.73% | 1,171,449 | SC 13G/A | |
| Jan 27, 2022 | blackrock inc. | 15.8% | 10,675,397 | SC 13G/A | |
| Jan 25, 2022 | blackrock inc. | 15.8% | 10,675,397 | SC 13G | |
| Dec 10, 2021 | wellington management group llp | 4.96% | 3,358,378 | SC 13G/A |
LNTH Fair Value
Lantheus Holdings fair value in different scenarios
The table shows the Fair Value estimates for Lantheus Holdings for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | - - | - - | - - | - - | - - |
| Current Inflation | 15.06 -80.90% | 20.01 -74.62% | 28.79 -63.48% | 34.73 -55.94% | 40.60 -48.50% |
| Very High Inflation | - - | - - | - - | - - | - - |
Historical Lantheus Holdings Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Lantheus Holdings
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 15, 2023 | 144 | Notice of Insider Sale Intent | |
| Mar 14, 2023 | 144 | Notice of Insider Sale Intent | |
| Mar 10, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 4 | Insider Trading | |
| Mar 08, 2023 | 144 | Notice of Insider Sale Intent | |
| Mar 07, 2023 | 144 | Notice of Insider Sale Intent |
Latest Insider Trading transactions for LNTH
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-08 | Heino Mary Anne | sold | -751,793 | 74.7013 | -10,064 | president & ceo |
2023-03-07 | Blanchfield Paul | sold | -199,001 | 72.154 | -2,758 | chief operating officer |
2023-03-07 | Marshall Robert J. Jr. | sold | -350,236 | 72.154 | -4,854 | cfo and treasurer |
2023-03-07 | Montagut Etienne | sold | -254,776 | 72.154 | -3,531 | chief business officer |
2023-03-07 | Niedzwiecki Daniel | sold | -76,122 | 72.154 | -1,055 | see remarks |
2023-03-07 | Sabens Andrea | sold | -68,546 | 72.154 | -950 | chief accounting officer |
2023-03-06 | Niedzwiecki Daniel | sold | -658,781 | 72.561 | -9,079 | see remarks |
2023-03-06 | Sabens Andrea | sold | -559,082 | 72.561 | -7,705 | chief accounting officer |
2023-03-06 | Montagut Etienne | sold | -1,028,840 | 72.561 | -14,179 | chief business officer |
2023-03-06 | Marshall Robert J. Jr. | sold | -1,493,810 | 72.561 | -20,587 | cfo and treasurer |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
LNTH Income Statement
2022-12-31Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Income Statement [Abstract] | |||
| Revenues | $ 935,061 | $ 425,208 | $ 339,410 |
| Cost of goods sold | 353,358 | 237,513 | 200,649 |
| Gross profit | 581,703 | 187,695 | 138,761 |
| Operating expenses | |||
| Sales and marketing | 100,243 | 68,422 | 40,901 |
| General and administrative | 133,584 | 150,395 | 69,270 |
| Research and development | 311,681 | 44,966 | 32,788 |
| Total operating expenses | 545,508 | 263,783 | 142,959 |
| Gain on sales of assets | 0 | 15,263 | 0 |
| Operating income (loss) | 36,195 | (60,825) | (4,198) |
| Interest expense | 7,185 | 7,752 | 9,479 |
| Loss (gain) on extinguishment of debt | 588 | (889) | 0 |
| Other loss (income) | 1,703 | 7,350 | (2,198) |
| Income (loss) before income taxes | 26,719 | (75,038) | (11,479) |
| Income tax (benefit) expense | (1,348) | (3,759) | 1,994 |
| Net income (loss) | $ 28,067 | $ (71,279) | $ (13,473) |
| Net income (loss) per common share: | |||
| Basic (in dollars per share) | $ 0.41 | $ (1.06) | $ (0.25) |
| Diluted (in dollars per share) | $ 0.40 | $ (1.06) | $ (0.25) |
| Weighted-average common shares outstanding: | |||
| Basic (in shares) | 68,487 | 67,486 | 54,134 |
| Diluted (in shares) | 70,671 | 67,486 | 54,134 |
LNTH Balance Sheet
2022-12-31Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $ 415,652 | $ 98,508 |
| Accounts receivable, net | 213,397 | 89,336 |
| Inventory | 35,475 | 35,129 |
| Other current assets | 13,092 | 12,818 |
| Total current assets | 677,616 | 235,791 |
| Property, plant and equipment, net | 122,166 | 116,772 |
| Intangibles, net | 315,285 | 348,510 |
| Goodwill | 61,189 | 61,189 |
| Deferred tax assets, net | 110,647 | 62,764 |
| Other long-term assets | 34,355 | 38,758 |
| Total assets | 1,321,258 | 863,784 |
| Current liabilities | ||
| Current portion of long-term debt and other borrowings | 354 | 11,642 |
| Accounts payable | 20,563 | 20,787 |
| Short-term contingent liability | 99,700 | 0 |
| Accrued expenses and other liabilities | 127,084 | 58,068 |
| Total current liabilities | 247,701 | 90,497 |
| Asset retirement obligations | 22,543 | 20,833 |
| Long-term debt, net and other borrowings | 557,712 | 163,121 |
| Other long-term liabilities | 46,155 | 124,894 |
| Total liabilities | 874,111 | 399,345 |
| Commitments and contingencies (see Note 20) | ||
| Stockholders’ equity | ||
| Preferred stock ($0.01 par value, 25,000 shares authorized; no shares issued and outstanding) | 0 | 0 |
| Common stock ($0.01 par value, 250,000 shares authorized; 68,851 and 67,739 shares issued as of December 31, 2022 and 2021, respectively) | 689 | 677 |
| Additional paid-in capital | 715,875 | 685,472 |
| Treasury Stock at cost - 1,339 and no shares as of December 31, 2022 and 2021, respectively | (75,000) | 0 |
| Accumulated deficit | (193,158) | (221,225) |
| Accumulated other comprehensive loss | (1,259) | (485) |
| Total stockholders’ equity | 447,147 | 464,439 |
| Total liabilities and stockholders’ equity | $ 1,321,258 | $ 863,784 |